The official blog of the Lung Institute.

Is Cell Therapy the Future of Medicine?

14 Sep 2015
| Under Lung Disease | Posted by
Is Cell Therapy the Future of Medicine?

Cell therapy helps those with progressive diseases promote healing in tissue to slow or stop the progression of the disease. Lung disease patients in particular have seen positive results following cell therapy because it naturally heals lung tissue. This minimally invasive procedure harnesses the body’s innate healing ability and allows many patients to get off of daily medications and supplemental oxygen. With a push toward more natural remedies, will cell therapy be the future of medicine?

Past Developments in Medicine

Lung disease is a progressive disease with a dire prognosis. Similarly, tuberculosis, a disease that causes fever, fatigue and chronic cough had been a deadly killer for thousands of years and was so widespread that it earned the nickname “White Plague.” The disease has been around for over 20,000 years and it wasn’t until the early 1920s when a vaccine and antibiotic in the form of streptomycin were discovered.

Streptomycin was discovered in 1944, and is a particularly noteworthy advancement because before streptomycin, surgical treatment of tuberculosis was common and was often life-saving. The surgery was developed by a Scottish physician, Dr. James Carson, and involved draining fluid from around the lungs and helped prolong the tuberculous sufferer’s life. The development of streptomycin eliminated the need for an invasive surgical procedure.

Similarly, some who suffer from progressive lung diseases like chronic obstructive pulmonary disease (COPD), interstitial lung disease and pulmonary fibrosis face a lung reduction or transplant in the later stages of the disease. These highly invasive surgeries do not have great long-term success rates. 78 percent of patients survive the first year after receiving a lung transplant. About 63 percent survive for three years, and only 51 percent survive five years. Not to mention after receiving a lung transplant, that person will likely be taking anti-rejection medication daily for the rest of their life. This has caused many lung disease sufferers to seek alternative treatment options.

Cell Therapy is Helping Patients Today

Cell therapy is an increasingly popular, minimally invasive alternative treatment for lung disease that is helping people in the United States today. The therapy may accelerate the body’s natural healing process to promote the healing of damaged lung tissue. Many lung disease patients may reduce, or even quit medications and supplemental oxygen after discussing it with their doctor. Cell therapy can help patients onto the path to recovery and free them from having to choose between having a lung transplant or falling into a steep, end-stage decline.

Future Advancements

Cell therapy isn’t a cure for lung disease, however, it may slow the progression or even improve lung function in some patients. While it doesn’t work for everyone, it helps the vast majority of patients and has better long-term results than traditional options. Like streptomycin, cell therapy may be the answer to providing better care for patients and has the potential to eliminate the need for surgery. Streptomycin was an integral part in curbing the damage caused by tuberculosis, once a widespread problem, now a rarity in the Western world. Perhaps cell therapy is the answer for lung disease sufferers today, providing them with a better option to breathe easier.

If you or a loved one suffers from lung disease, the Lung Institute may be able to help. Contact one of our patient coordinators today at 888-745-6697 to learn more about cell therapy for lung disease.

*For more information, go to www.LungInstitute.com/Results.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.